Europe Anatomic Pathology Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The anatomic pathology market is projected to grow significantly, reaching approximately USD 14.99 billion by 2031, up from USD 8.46 billion in 2023. This growth represents a compound annual growth rate (CAGR) of 7.4% from 2023 to 2031.

Executive Summary and European Market Overview

In Europe, the anatomic pathology market is divided into several key countries, including Germany, France, the UK, Italy, Spain, and other regions. The growth of this market in Europe is primarily driven by the increasing incidence of cancers, particularly cervical and breast cancer. Additionally, various cancer screening initiatives implemented by health authorities aim to lower the prevalence of chronic diseases, which is expected to create further growth opportunities in the market.

Market Segmentation Analysis

The European anatomic pathology market can be analyzed through several segments: products and services, applications, and end users.

1. Products and Services: The market is categorized into services, instruments, and consumables. In 2023, instruments accounted for the largest market share. The services segment is further divided into histopathology and cytopathology, while the instruments segment includes microtomes, cryostats, automatic stainers, tissue processors, and other related tools.
2. Applications: The market is segmented based on applications into disease diagnosis, drug discovery and development, and other areas. The disease diagnosis segment held the largest share in 2023, reflecting the critical role of anatomic pathology in identifying various diseases.
3. End Users: The end-user segmentation includes hospitals, research laboratories, diagnostic laboratories, and others. Hospitals represented the largest share of the market in 2023, highlighting their central role in disease diagnosis and treatment.

Market Outlook

Anatomic pathology plays a crucial role in diagnosing various diseases, including autoimmune disorders, kidney and liver diseases, and cancers. Histopathology, which focuses on examining tissue changes due to diseases, is particularly vital in cancer diagnosis. Cancer remains a significant global health challenge, being one of the leading causes of death worldwide. The World Health Organization (WHO) identifies cancer as the second leading cause of mortality globally. In 2022, approximately 20 million new cancer cases were reported, and nearly 10 million deaths were attributed to cancer in 2020. In the UK alone, around 392,000 new cancer diagnoses occur annually, with approximately 167,000 deaths each year due to the disease.

The rising prevalence of chronic kidney disease, driven by an aging population, further emphasizes the importance of anatomic pathology techniques such as biopsies for detecting cancer and kidney diseases. As the incidence of cancer and other chronic diseases rises, healthcare providers, government agencies, and institutions are increasingly focused on enhancing disease diagnosis and treatment initiatives. This trend is expected to propel the growth of the anatomic pathology market in Europe.

Country-Specific Insights

The European anatomic pathology market includes key countries such as the UK, Germany, France, Italy, Spain, and others. Germany held the largest market share in 2023, largely due to the significant recognition of cytology, especially in relation to cervical cancer screening programs. The German government has been proactive in improving medical infrastructure, particularly through its cervical cancer screening program, which was updated in January 2020 to include co-testing for cytology and human papillomavirus (HPV) every three years for women aged 35 and older.

The increase in cervical cancer cases has led to a rise in screening initiatives across Germany. Recent studies indicate that cytology remains a critical component of cervical cancer screening, and the implementation of mass primary high-risk HPV screening may contribute to the eventual elimination of cervical cancer. The presence of esteemed research institutions in Germany also supports the advancement of innovative pathology tests aimed at early disease detection and prevention. For instance, the Institute for Pathology in Cologne processes around 40,000 surgical specimens and conducts 150 postmortems annually, underscoring the robust pathology services available in the country.

Company Profiles

Key players in the European anatomic pathology market include F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, Hologic Inc, Agilent Technologies Inc, Diapath S.p.A., Bio SB, Merck KGaA, and PHC Holdings Corporation, among others. These companies are employing various strategies, including market expansion, product innovation, and mergers and acquisitions, to enhance their offerings and increase their market presence.

In conclusion, the European anatomic pathology market is poised for substantial growth, driven by the rising prevalence of cancer and chronic diseases, alongside ongoing advancements in medical technology and screening initiatives.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe anatomic pathology market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in Europe anatomic pathology market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the anatomic pathology market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.